A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1

Postoperative Recovery Clinical Trial

Official title:

A Single-center Study on the Effect of Systemic/Selective Lymph Node Dissection on the Prognosis of Ground Glass Nodules Smaller Than 3cm and With Components With Consolidation/Tumor Ratio Between 0.5-1

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05184829
• Other study ID #: B2021
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 1, 2022
• Est. completion date: December 31, 2029

Study information

• Verified date: December 2021
• Source: Shanghai Zhongshan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A single-center study on the effect of systemic/selective lymph node dissection on the prognosis of ground glass nodules smaller than 3cm and with components with consolidation/tumor ratio between 0.5-1

Description:

A single-center study on the effect of systemic/selective lymph node dissection on the prognosis of ground glass nodules smaller than 3cm and with components with consolidation/tumor ratio between 0.5-1

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 500
• Est. completion date: December 31, 2029
• Est. primary completion date: December 31, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 25 Years to 75 Years

Eligibility

Inclusion Criteria:

Patients enrolled in the study must meet all of the following conditions:

• 1.Aged between 25 and 75 years;
• 2. GGO is diagnosed by thin-section lung CT (thickness <1.5mm) within one month before surgery;
• 3. The maximum diameter of the GGO is smaller than 3cm;
• 4. The solid component in GGO between 50%-100%;
• 5. Preoperative examination showed that the patient could tolerate lobectomy;
• 6. The patient is able to understand and comply with the study and has provided written informed consent. Exclusion Criteria:

Patients meeting any of the following criteria are not eligible for this trial:

• 1. Patients with a history of lung surgery;
• 2. Postoperative pathology showed non-primary lung cancer;
• 3. The scope of surgical resection is larger than one lung lobe;
• 4. Patients with a history of other tumors;
• 5. Patients with severe complications (coronary heart disease, valvular heart disease, end-stage renal disease, severe liver cirrhosis);
• 6. Unable to cooperate with the researchers because of dementia or cognitive decline
• 7. Other situations that are not in conformity with the standards and requirements of this trial.

Related Conditions & MeSH terms

• Disease Progression
• Postoperative Recovery
• Progression

Intervention

Other:
• selective lymph node dissection
selective lymph node dissection
• Systemic Lymph Node Dissection
Systemic Lymph Node Dissection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Shanghai Zhongshan Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		From enrollment to 36 months after surgery
Secondary	Complications	The degrees of cough	1-2 Weeks after enrollment (after Surgery)